Cargando…
Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B
There is no cure or beneficial management option for Limb-Girdle muscular dystrophy (MD) type 2B (LGMD2B). Losartan, a blood pressure (BP) lowering angiotensin II (AngII) receptor type 1 (ATR1) blocker (ARB) with unique anti-transforming growth factor-β (TGF-β) properties, can protect muscles in var...
Autores principales: | White, Zoe, Milad, Nadia, Tehrani, Arash Y., Chen, William Wei-Han, Donen, Graham, Sellers, Stephanie L., Bernatchez, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690544/ https://www.ncbi.nlm.nih.gov/pubmed/31404091 http://dx.doi.org/10.1371/journal.pone.0220903 |
Ejemplares similares
-
Limb-girdle muscular dystrophy type 2B causes HDL-C abnormalities in patients and statin-resistant muscle wasting in dysferlin-deficient mice
por: White, Zoe, et al.
Publicado: (2022) -
Humanization of the mdx Mouse Phenotype for Duchenne Muscular Dystrophy Modeling: A Metabolic Perspective
por: Donen, Graham, et al.
Publicado: (2023) -
Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy
por: Milad, Nadia, et al.
Publicado: (2017) -
Effect of Dysferlin Deficiency on Atherosclerosis and Plasma Lipoprotein Composition Under Normal and Hyperlipidemic Conditions
por: White, Zoe, et al.
Publicado: (2021) -
Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations
por: Cacciottolo, Mafalda, et al.
Publicado: (2011)